Teva launches generic Baraclude tabs

JERUSALEM — Teva Pharmaceutical on Thursday announced the launch of generic Baraclude (entecavir) tablets in 0.5-mg and 1-mg dosage strengths. The company was the first to file, giving it 180 days of marketing exclusivity for the drug. 

 

Baraclude (entecavir) tablets are marketed by Bristol-Myers Squibb and had annual sales of $328 million in the United States as of June 2014, according to IMS data. The drug is indicated as a treatment for chronic hepatitis B virus infection.